Insights into the structure and function of 5-HT₂ familyserotonin receptors reveal novel strategies for therapeutic target development

Bibliography

• HOYER D, MARTIN G: 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology (1997) 36:419–428.
   PubMed Web of Science ®Google Scholar
• ROTH BL, LOPEZ E, PATEL S, KROEZE W: Multiplicity of serotonin receptors: useless diverse molecules or an embarrassement of riches? The Neuroscientist (2000) 6:252–262.
   Web of Science ®Google Scholar
• ROTH BL, MELTZER H: The role of serotonin in schizophnrenia. In: Psychophannacology: The Fourth Generation of Progress. Bloom F, Kupfer D (Eds.), Raven Press, (1995):1215–1227.
   Google Scholar
• KROEZE WK, ROTH BL: The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol. Psychia. (1998) 44:1128–1142.
   PubMed Web of Science ®Google Scholar
• ••Excellent comprehensive review of receptor subtypes, receptor-drug interactions with an emphasis on specificity/non-specificity, and what is currently known about the molecular interactions governing the psychopharmacology.
   Google Scholar
• MAES M, MELTZER H: The role of serotonin in depression. In: Psychopharmacology: a Fourth Generation of Progress. Edited by; 1994
   Google Scholar
• ZHUANG X, GROSS C, SANTARELLI L, COMPAN V, TRILLAT AC, HEN R: Altered emotional states in knockout mice lacking 5-HT or 5-HT 113 receptors. Neuropsychopharmacology (1999) 21:52S–60S.
   Google Scholar
• CHARNEY DS, GOODMAN WK, PRICE LH, WOODS SW, RASMUSSEN SA, HENINGER GR: Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch. Gen. Psych. (1988) 45:177–185.
   PubMed Web of Science ®Google Scholar
• TECOTT LH, SUN LM, AKANA SF et al:Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1995) 374:542–546.
   PubMed Web of Science ®Google Scholar
• CROWELL MD: The role of serotonin inthe pathophysiology of irritable bowel syndrome. Am. .1. Manag. Care (2001) 7:S252–260.
   PubMed Web of Science ®Google Scholar
• WHORWELL PJ: Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards. Gut (2001) 48:596–597.
   PubMed Web of Science ®Google Scholar
• FOZARD JR, KALKMAN HO: 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedebergs Arch. Pharmacol. (1994) 350:225–229.
   PubMed Web of Science ®Google Scholar
• HASLER WL: Serotonin receptor physiology: relation to emesis. Dig. DA. (1999) 44:108S–113S.
   Google Scholar
• SUMPTON JE, MOULIN DE: Treatment of neuropathic pain with venlafaxine. Ann. Pharmacother: (2001) 35:557–559.
   PubMed Web of Science ®Google Scholar
• ATTAL N: Pharmacologic treatment of neuropathic pain. Acta Neurol Belg. (2001) 101:53–64.
   PubMed Web of Science ®Google Scholar
• OCHI T, GOTO T: The antinociceptiveeffect induced by FR140423 is mediated through spinal 5-HT 2A and 5-HT3 receptors. Eui: Phannacol (2000) 409:167–172.
   PubMed Web of Science ®Google Scholar
• VICKERS T, CLIFTON PG, DOURISH CT, TECOTT LH: Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2c) receptor mutant mice. Psychopharmacology (Berl) (1999) 143:309–314.
   PubMed Web of Science ®Google Scholar
• POLLOCK BG, MULSANT BH: Behavioral disturbances of dementia.' Geriatr. Psychia. Neurol (1998) 11:206–212.
   PubMed Web of Science ®Google Scholar
• CARLSSON ML, MARTIN P, NILSSON M et al: The 5-HT 2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.' Neural Transm. (1999) 106:123–129.
   PubMed Web of Science ®Google Scholar
• APTER JT, ALLEN LA: Buspirone: futuredirections. I Clin. Psychopharmacol (1999) 19:86–93.
   Google Scholar
• ROTH BL, WILLINS DL, KROEZE WK: G-protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Drug Alcohol. Depend. (1998) 51:73–85.
   PubMed Web of Science ®Google Scholar
• ROTH BL, WILLINS DL, KRISTIANSEN K, KROEZE WK: 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5- hydroxy-tryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Thec (1998) 79:231–257.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive treatise discussing thedomains in 5-HT2 receptors important for ligand binding, receptor activation, receptor internalisation, and more.
   Google Scholar
• ROTH BL, WILLINS D, KRISTIANSEN K, KROEZE W: Activation is hallucinogenic and antagonism is therapeutic: role of 5-HT 2A receptors in atypical antipsychotic drug actions. The Neuroscientist (1999) 5:254–262.
   Web of Science ®Google Scholar
• MELTZER HY: Outcome in schizophrenia: beyond symptom reduction. I Clin. Psychiatry (1999) 60:3–7.
   PubMed Web of Science ®Google Scholar
• BLAZER DG, KESSLER RC, MCGONAGLE KA, SWARTZ MS: The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. Psychiatry (1994) 151:979–986.
   PubMed Web of Science ®Google Scholar
• BAKER RA, ANDREW MJ, SCHRADER G, KNIGHT JL: Preoperative depression and mortality in coronary artery bypass surgery: preliminary findings. ANZJ Sing. (2001) 71:139–142.
   Google Scholar
• CARNEY RM, FREEDLAND KE, JAFFE AS: Depression as a risk factor for coronary heart disease mortality. Arch. Gen. Psych. (2001) 58:229–230.
   PubMed Web of Science ®Google Scholar
• VACCARINO V, KASL SV, ABRAMSON J, KRUMHOLZ HM: Depressive symptoms and risk of functional decline and death in patients with heart failure. j. Am. Coll. Cardiol (2001) 38:199–205.
   PubMed Web of Science ®Google Scholar
• JEFFERY RW: Public health strategies for obesity treatment and prevention. Am. Health Behav. (2001) 25:252–259.
   PubMed Web of Science ®Google Scholar
• STYNE DM: Childhood and adolescent obesity. Prevalence and significance. Pediati: Gin. North Am. (2001) 48:823–854.
   PubMed Web of Science ®Google Scholar
• CONNOLLY HM, MCGOON MD: Obesity drugs and the heart. Curc Pro& Cardiol (1999) 24:745–792.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, MATSUBARA S, LEE JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Pharmacol Exp. Therap. (1989) 251:238–246.
   PubMed Web of Science ®Google Scholar
• MARTIN BC, MILLER LS, KOTZAN JA:Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr. Res. (2001) 47:281–292.
   PubMed Web of Science ®Google Scholar
• FRANGOU S, LEWIS M: Atypical antipsychotics in ordinary clinical practice: a pharmaco- epidemiologic survey in a south London service. Eur: I Psychiatry (2000) 15:220–226.
   PubMed Web of Science ®Google Scholar
• WETTERLING T: Bodyweight gain with atypical antipsychotics. A comparative review. Drug Sal (2001) 24:59–73.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: Suicide in schizophrenia: risk factors and clozapine treatment. J. Clin. Psychiatry (1998) 59:15–20.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, OKAYLI G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. I Psychiatry (1995) 152:183–190.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: Clozapine: clinical advantages and biological mechanisms. In: Schizophrenia: A scientific focus. Schulz SC, Tamminga C (Eds.), Oxford University Press, (1989):302–309
   Google Scholar
• PAL VIMAKI EP, ROTH BL, MAJASUO H et al.: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) (1996) 126:234–240.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, HYTTEL J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell MM. Neurobiol (1999) 19:467–489.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G, PERRAULT G, SANGER DJ: A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology (1997) 36:793–802.
   PubMed Web of Science ®Google Scholar
• MILLAN MJ, GOBERT A, RIVET JM et al.: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2- adrenergic and serotonin 2C receptors: a comparison with citalopram. Eur: Neurosci (2000) 12:1079–1095.
   PubMed Web of Science ®Google Scholar
• MARTIN JR, BOS M, JENCK F et al.: 5-HT2c receptor agonists: pharmacological characteristics and therapeutic potential. .1 Pharmacol Exp. The]: (1998) 286:913–924.
   Google Scholar
• ROTH BL: Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry (1994) 6:67–78.
   PubMedGoogle Scholar
• LIGHTOWLER S, WOOD M, BROWN T et al.: An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats. Eric I Pharmacol (1996) 296:137–143.
   PubMed Web of Science ®Google Scholar
• CURZON G, GIBSON EL, OLUYOMI AO: Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci. (1997) 18:21–25.
   PubMed Web of Science ®Google Scholar
• CONNOLLY J, VERNI C, TRILLING J, KELSO E, SHIESHA S: Selections from current literature: pharmacological treatment of obesity. Fain. Pract. (1998) 15:88–93.
   PubMed Web of Science ®Google Scholar
• FITZGERALD LW, BURN TC, BROWN BS et al.: Possible role of valvular serotonin 5-HT(2R receptors in the cardiopathy associated with fenfluramine. MM. Pharmacol (2000) 57:75–81.
   PubMed Web of Science ®Google Scholar
• ROTHMAN RB, BAUMANN MH, SAVAGE JE et al: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 102:2836–2841.
   PubMed Web of Science ®Google Scholar
• •Discusses the potential involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenflurarnine use.
   Google Scholar
• CHOUDHARY MS, CRAIGO S, ROTH BL: A single point mutation (Phe340>Leu34°) of a conserved phenylalanine abolishes 4- [125I]iodo- (2,5-dimethoxy)phenylisopropylamine and [3I-I]mesulergine but not [3I-I]ketanserin binding to 5-hydroxytryptamine2 receptors. MM. Pharmacol. (1993) 43:755–761.
   PubMed Web of Science ®Google Scholar
• CHOUDHARY MS, SACHS N, ULUER A, GLENNON RA, WESTKAEMPERRB, ROTH BL: Differential ergoline and ergopeptine binding to 5-hydroxy-tryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding [published erratum appears in Mol. Pharmacol (1995) 48(3):568]. Mol. Pharmacol (1995) 47:450–457.
   Google Scholar
• SHAPIRO DA, KRISTIANSEN K, KROEZE WK, ROTH BL: Differential modes of agonist binding to 5-Hydroxytryptamine (2fto serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol. Pharmacol. (2000) 58:877–886.
   PubMed Web of Science ®Google Scholar
• ROTH B, SHOHAM M, CHOUDHARY M, KHAN N: Identification of conserved aromatic residues essential for agonist binding and efficacy at 5-HT 2A receptors. MM. Pharmacol (1997) 52:259–266.
   PubMed Web of Science ®Google Scholar
• ALMAULA N, EBERSOLE BJ, BALLESTEROS JA, WEINSTEIN H, SEALFON SC: Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxy-tryptamine2c receptors: direct and indirect effects on ligand affinity mediated by the same locus. MM. Pharmacol. (1996) 50:34–42.
   PubMed Web of Science ®Google Scholar
• ALMAULA N, EBERSOLE BJ, ZHANG D, WEINSTEIN H, SEALFON SC: Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36 (159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J. Biol. Chem. (1996) 271:14672–14675.
   Google Scholar
• VVESTKAEMPER RB, RUNYON SP, SAVAGE JE, ROTH BL, GLENNON RA: Exploring the relationship between binding modes of 9-(aminomethyl)- 9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2Aserotonin receptor. Bioorg. Med. Chem. Lett. (2001) 11:563–566.
   PubMed Web of Science ®Google Scholar
• RUNYON SP, SAVAGE JE, TAROUA M, ROTH BL, GLENNON RA, VVESTKAEMPER RB: Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethy0-9,10-dihydroanthracene. Bioorg. Med. Chem. Lett (2001) 11:655–658.
   PubMed Web of Science ®Google Scholar
• WESTKAEMPER R, GLENNON R, HYDE E, CHOUDHARY M, KHAN N, ROTH B: Engineering in a region of bulk tolerance into the 5-HT 2A receptor. Eur: Med. Chem. (1999) 34:441–447.
   Google Scholar
• KRISTIANSEN K, KROEZE W, WILLINS D et al.: A highly conserved aspartic acid (D155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT 2A serotonin receptor but does not participate in activation via a 'salt-bridge disruption' mechanism.' Pharmacol. Exp. Thei: (2000) 293:735–746.
   Google Scholar
• WANG CD, GALLAHER TK, SHIH JC: Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. MM. Pharmacol (1993) 43:931–940.
   PubMed Web of Science ®Google Scholar
• PALCZEWSKI K, KUMASAKA T, HORI T et al.: Crystal structure of rhodopsin: A G-protein-coupled receptor. Science (2000) 289:739–745.
   PubMed Web of Science ®Google Scholar
• •The first crystal structure of a GPCR, bovine rhodopsin, solved to 2.8A.
   Google Scholar
• GELBER El, KROEZE WK, WILLINS DL et al: Structure and function of the third intracellular loop of the 5- hydroxy-tryptamine2A receptor: the third intracellular loop is alpha- helical and binds purified arrestins.j. Neurochem. (1999) 72:2206–2214.
   PubMed Web of Science ®Google Scholar
• CHOUDHARY MS, CRAIGO S, ROTH BL: Identification of receptor domains that modify ligand binding to 5- hydroxy-tryptamine2 and 5-hydroxytryptamine1c serotonin receptors. Mol. Pharmacol (1992) 42:627–633.
   PubMed Web of Science ®Google Scholar
• KRISTIANSEN KD, SG: Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2c receptor interactions. Eur: Pharmacol. (1996) 306:195–210.
   PubMed Web of Science ®Google Scholar
• KRISTIANSEN KD, SG, EDVARDSEN, O: A database of mutants and effects of site-directed mutagenesis experiments on G-protein-coupled receptors. In: PROTEINS: Structure, function and genetics (Volume 26). Tromso, Norway: Institute of Medical Biology, University of Tromso (1996):81–94.
   Google Scholar
• ALTAR CA, WASLEY AM, NEALE RE STONE GA: Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. (1986) 16:517–525.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN K, AGHAJANIAN GK: Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology (1988) 1:101–107.
   PubMed Web of Science ®Google Scholar
• JANSSEN PA, NIEMEGEERS CJ, AWOUTERS F, SCHELLENKENS KH, MEGENS AA, MEERT TF: Pharmacology of risperidone (R 64,766) a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Pharmacol. Exp. Ther. (1988) 244:685–693.
   PubMed Web of Science ®Google Scholar
• KANE J, HONIGFIELD G, SINGER J, MELTZER HY: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psy (1988) 45:789–796.
   PubMed Web of Science ®Google Scholar
• BYMASTER FC, FAL CONE JF MARSH RD: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology (1996) 14:87–96.
   PubMed Web of Science ®Google Scholar
• ROTH BL, TANDRA S, BURGESS LH, SIBLEY DR, MELTZER HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) (1995) 120:365–368.
   PubMed Web of Science ®Google Scholar
• SALLER CE SALAMA Al: Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (1993) 112:285–292.
   PubMed Web of Science ®Google Scholar
• SEEGER TF, SEYMOUR PA, SCHMIDT AW et al: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.' Pharmacol. Exp. Ther. (1995) 275:101–113.
   PubMed Web of Science ®Google Scholar
• MASON SL, REYNOLDS GP: Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur: .1. Pharmacol (1992) 221:397–398.
   Google Scholar
• ROLLEMA H, LU Y, SCHMIDT AW, ZORN SH: Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur: Pharmacol (1997) 338:R3–R5.
   Web of Science ®Google Scholar
• NEWMAN-TANCREDI A, GAVAUDAN S, CONTE C et al: Agonist and antagonist 693 actions of antipsychotic agents at 5-HT1A receptors: a [3S1GTPgammaS binding study. Eur.J Pharmacol (1998) 355:245–256.
   PubMed Web of Science ®Google Scholar
• ROTH BL, CIARANELLO RD, MELTZER HY: Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1c receptors. J. Pharmacol Exp. Ther. (1992) 260:1361–1365.
   PubMed Web of Science ®Google Scholar
• ROTH BL, CRAIGO SC, CHOUDHARY MS et al.: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol Exp. The,: (1994) 268:1403–1410.
   Google Scholar
• VAN TOL HHM, BUNZOW JR, GUAN HC et al.: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350:610–614.
   PubMed Web of Science ®Google Scholar
• GILLILAND SL, ALPER RH: Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S] GTPgammaS binding assays. Naunyn Schmiedebergs Arch. Pharmacol (2000) 361:498–504.
   Google Scholar
• BOLDEN C, CUSACK B, RICHELSON E: Antagonism by anitmuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in chinese hamster ovary cells.' Pharmacol Exp. Therap. (1992) 260:576–580.
   PubMed Web of Science ®Google Scholar
• ZENG XP, LE F, RICHELSON E: Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Ear: Pharmacol (1997) 321:349–354.
   PubMed Web of Science ®Google Scholar
• ROTH B, MELTZER H, KHAN N: Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. In Advances M Pharmacology (Volume 42). Goldstein D, Eisenhoffer G, McCarty R (Eds.) Academic Press, (1998):482–485.
   Google Scholar
• SORENSEN SM, KEHNE JH, FADAYEL EM et al: Characterization of the 5-HT2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. Pharmacol Exp. The]: (1993) 266:684–691.
   Google Scholar
• DE PAULIS T: M-100907 (Aventis). Opin. Investig. Drugs (2001) 2:123–132.
   Google Scholar
• DUINKERKE SJ, BOTTER PA, JANSEN AA et al.: Ritanserin, a selective 5-HT2jic antagonist and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry (1993) 163:451–455.
   PubMed Web of Science ®Google Scholar
• CHRISTENSSON E, BJORK A: Amperozide: a new pharmacological approach in the treatment of schizophrenia. Pharmacologie et Toxicologic. (1990) 66:5–7.
   Google Scholar
• AXELSSON R, NILSSON A, CHRISTENSSON E, BJORK A: Effects of amperozide in schizophrenia: an open study of a potent 5-HT2 receptor antagonist. Psychopharmacology (Berl) (1991) 104:287–292.
   PubMed Web of Science ®Google Scholar
• TRUFFINET P, TAMMINGA CA, FABRE LF, MELTZER HY, RIVIERE ME, PAPILLON-DOWNEY C: Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am. J. Psychiatry (1999) 156:419–425.
   PubMed Web of Science ®Google Scholar
• NARENDRAN R, YOUNG CM, VALENTI AM, PRISTACH CA, PATO MT, GRACE JJ: Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. Clin. Psychiatry (2001) 62:509–516.
   PubMed Web of Science ®Google Scholar
• SANGER TM, GRUNDY SL, GIBSON PJ, NAMJOSHI MA, GREANEY MG, TOHEN MF: Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. Clin. Psychiatry (2001) 62:273–281.
   PubMed Web of Science ®Google Scholar
• GHAEMI SN, CHERRY EL, KATZOW JA, GOODWIN FK: Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord (2000) 2:196–199.
   PubMed Web of Science ®Google Scholar
• LINDSTROM LH: A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology (Berl) (1989) 99:S84–S86.
   Web of Science ®Google Scholar
• MCELROY SL, DESSAIN EC, POPE HG, Jr. et al: Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder and schizophrenia. Clin. Psychiatry (1991) 52:411–414.
   PubMed Web of Science ®Google Scholar
• TAYLOR DM, MCASKILL R: Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr. Scand. (2000) 101:416–432.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, MCCANN SM, KENNEDY SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Can. I Psychiatry (2001) 46:273–281.
   PubMed Web of Science ®Google Scholar
• FONTAINE KR, HEO M, HARRIGAN EP et al.: Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. (2001) 101:277–288.
   PubMed Web of Science ®Google Scholar
• YAMADA M, MIYAKAWA T, DUTTAROY A et al.: Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature (2001) 410:207–212.
   PubMed Web of Science ®Google Scholar
• WIRSHING DA, WIRSHING WC, KYSAR L et al.: Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psycho]. (1999) 60: 358–363.
   PubMed Web of Science ®Google Scholar
• PEROUTKA SJ, SNYDER SH: PHIMianserin: differential labeling of serotonin and histamine receptors in rat brain. J. Pharmacol Exp. Ther. (1981) 216:142–148.
   PubMed Web of Science ®Google Scholar
• LANGER SZ: 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol Sci (1997) 18:95–99.
   PubMed Web of Science ®Google Scholar
• ABED RT, COOPER M: Mirtazepine causing hyperphagia. Br. J. Psychiatry(1999) 174:181.
   PubMed Web of Science ®Google Scholar
• FIORELLA D, RABIN RA, WINTER JC: The role of the 5-HT2A and 5-HT2c receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl) (1995) 119:222–230.
   PubMed Web of Science ®Google Scholar
• SCOTT JA, CREWS FT: Down-regulation of serotonin2, but not of beta-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin2 and beta-adrenergic receptors. Neuropharmacology (1986) 25:1301–1306.
   PubMed Web of Science ®Google Scholar
• SHARPLEY AL, ELLIOTT JM, ATTENBURROW MJ, COWEN PJ: Slow wave sleep in humans: role of 5-HT2A and 5-HT2c receptors. Neuropharmacology (1994) 33:467–471.
   PubMed Web of Science ®Google Scholar
• KENNETT GA, WOOD MD, GLEN A et al.: In vivo properties of SB 200646A, a 5-HT2u2B receptor antagonist. Br. J. Pharmacol (1994) 111:797–802.
   PubMed Web of Science ®Google Scholar
• KENNETT GA, PITTAWAY K, BLACKBURN TP: Evidence that 5-HT2c receptor antagonists are amdolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl) (1994) 114:90–96.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G: 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther. (1995) 65:319–395.
   PubMed Web of Science ®Google Scholar
• •An overview of 30 years of behavioural data literature involving 5-HT neurotransmission in the regulation of anxiety. Ha BENJAMIN J, GREENBERG BD, MURPHY DL: Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology (Berl) (1996) 127:140–149.
   Google Scholar
• WOOD MD, REAVILL C, TRAIL B et al: SB-243213; a selective 5-HT2c receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology (2001) 41:186–199.
   PubMed Web of Science ®Google Scholar
• BROMIDGE SM, DABBS S, DAVIES Set al.:1- [2- RHeteroaryloxy) heteroarylIcarbamoyllindolines: novel and selective 5-HT2c receptor inverse agonists with potential as antidepressant/anxiolytic agents. Bioorg. Med. Chem. Lett. (2000) 10:1863–1866.
   Google Scholar
• DELGADO PL, MORENO FA: Hallucinogens, serotonin and obsessive-compulsive disorder. Psychoactive Drugs (1998) 30:359–366.
   PubMed Web of Science ®Google Scholar
• PERRINE DM: Hallucinogens and obsessive-compulsive disorder. Am. J Psychiatry (1999) 156:1123.
   PubMed Web of Science ®Google Scholar
• BRANDRUP E, VANGGAARD T: LSD treatment in a severe case of compulsive neurosis. Acta Psychiatry Scand. (1977) 55:127–141.
   PubMed Web of Science ®Google Scholar
• CHOUINARD G: Sertraline in the treatment of obsessive-compulsive disorder: two double; blind placebo-controlled studies. hat. Clin. Psychopharmacol (1992) 7:37–41.
   PubMed Web of Science ®Google Scholar
• DAGOGO-JACK S: Human leptin regulation and promise in pharmacotherapy. Carr. Drug Targets (2001) 2:181–195.
   PubMed Web of Science ®Google Scholar
• PROIETTO J, FAM BC, AINSLIE DA, THORBURN AW: Novel anti-obesity drugs. Expert Opin. Investig. Drugs (2000) 9:1317–1326.
   PubMed Web of Science ®Google Scholar
• VERGONI AV, BERTOLINI A: Role of melanocortins in the central control of feeding. Eur: Pharmacol (2000) 405:25–32.
   PubMed Web of Science ®Google Scholar
• WARDEN NA,WARDEN CH: Biological influences on obesity. Pediatr. Clin. North Am. (2001) 48:879–891.
   PubMed Web of Science ®Google Scholar
• WILDING J: The future of obesity treatment. EXS (2000) 89:181–191.
   PubMedGoogle Scholar
• GLAZER G: Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch. Intern. Med. (2001) 161:1814–1824.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS ED, WEIR EK: Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am. Med. Sci (2001) 321:292–299.
   PubMed Web of Science ®Google Scholar
• MCCANN UD, YUAN J, RICAURTE GA: Neurotoxic effects of +/-fenfluramine and phenteramine, alone and in combination, on monoamine neurons in the mouse brain. Synapse (1998) 30:239–246.
   PubMed Web of Science ®Google Scholar
• PORTER RH, BEN WELL KR, LAMB H et al.: Functional characterization of agonists at recombinant human 5-HT, 5-HT2B and 5-HT2c receptors in CHO-Kl cells. Br. Pharmacol (1999) 128:13–20.
   PubMed Web of Science ®Google Scholar
• DOURISH CT: Multiple serotonin receptors: opportunities for new treatments for obesity? Obes. Res. (1995) 3 (Suppl. 4):449S–462S.
   Google Scholar
• •Exploration of the involvement of 5-HT/1B and 5-HT2c in the regulation of body weight.
   Google Scholar
• SANDOU F, AMARA DA, DIERICH A et al.: Enhanced aggressive behavior in mice lacking 5-HTm receptor. Science (1994) 265: 1875-1878.
   Google Scholar
• PIGOTT TA, HILL JL, GRADY TA et al: A comparison of the behavioral effects of oral verses intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol. Psychia. (1993) 33:3–14.
   PubMed Web of Science ®Google Scholar
• LYDIARD RB, BRAWMAN-MINTZER O, BALLENGER JC: Recent developments in the psychopharmacology of anxiety disorders. Consult. Gin. Psychol (1996) 64:660–668.
   PubMed Web of Science ®Google Scholar
• BLIER P, ABBOTT FV: Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. Psychiatry Neurosci. (2001) 26:37–43.
   PubMed Web of Science ®Google Scholar
• PEROUTKA SJ, MCCARTHY BG: Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur. Pharmacol (1989) 163:133–136.
   PubMed Web of Science ®Google Scholar
• SALZMAN C: Treatment of the agitation of late-life psychosis and Alzheimer's disease. Eur. Psychiatry (2001) 16 (Suppl. 1):25–28.
   Google Scholar